Summary of Nordson Corporation (NDSN) Q4 2025 Earnings Call

1Key Financial Results and Metrics

Q4 Sales: $752 million, up 1% year-over-year.

Adjusted EPS: $3.03, a 9% increase from the previous year, exceeding guidance.

Record EBITDA: $256 million, with an EBITDA margin of 34%.

Full Year Sales: $2.8 billion, a 4% increase from the previous year.

Adjusted EPS for FY 2025: $10.24, a 5% increase.

Free Cash Flow: $661 million, with a conversion rate of 136% of net income.

Net Debt: Approximately $1.9 billion, resulting in a leverage ratio of 2.1x.

2Strategic Updates and Business Highlights

Ascend Strategy: Continued success with the strategy, achieving record sales and EBITDA, and enhancing operational capabilities.

Portfolio Optimization: Successful integration of Atrion Medical and divestiture of the medical contract manufacturing business, leading to improved margins and focus on core medical operations.

Market Demand: Strong demand in medical and fluid solutions, with a return to mid-single-digit organic growth expected. Stability in automotive and polymer processing markets is anticipated.

3Forward Guidance and Outlook

Fiscal 2026 Sales Guidance: Expected to be between 1% to 6% above FY 2025 sales, with a midpoint of 3.5%.

Adjusted EPS Growth: Forecasted to grow between 6% to 12%, with a midpoint of 9%.

First Quarter FY 2026 Guidance: Sales expected in the range of $630 million to $670 million, with adjusted EPS between $2.25 and $2.45.

4Bad News, Challenges, or Points of Concern

Organic Sales Decline: Organic sales were down roughly 3% for the full year, primarily due to weaknesses in polymer processing and automotive-related systems.

Market Volatility: Despite positive trends, the company remains cautious about potential macroeconomic disruptions and the lumpiness of orders in the Advanced Technology Solutions segment.

Polymer Processing and Automotive: Both segments have been underperforming, although signs of stabilization are noted.

5Notable Q&A Insights

Semiconductor Applications: Continued strength in semiconductor applications, particularly in AI and cloud computing, but automotive and general electronics are stabilizing with lower growth rates.

Margin Trajectory: While strong margins were achieved, particularly in the medical segment, expectations for future margins should be tempered, with upper 30% margins considered sustainable rather than the 40% achieved in Q4.

Backlog Trends: Backlog is up 5% year-over-year but down sequentially, which is typical for Q1. The company anticipates a normal seasonal trend for FY 2026.

M&A Activity: The company remains focused on strategic acquisitions but has not executed any in FY 2025, prioritizing share repurchases instead. This summary encapsulates the key financial metrics, strategic initiatives, and outlook for Nordson Corporation, while also addressing challenges and insights from the Q&A session.